__NUXT_JSONP__("/drugs/Octreotide", (function(a,b){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[{brand:"Mycapssa",indication:"1 INDICATIONS AND USAGE MYCAPSSA is indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide (â€Ž 1 ).",manufacturer:"Chiasma Inc.",splSetId:"62a5e1eb-b48e-4ea6-8781-f75e490b17e4"}],id:a,nciThesaurus:{casRegistry:"83150-76-9",chebiId:"CHEBI:7726",chemicalFormula:"C49H66N10O10S2",definition:"A synthetic long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Octreotide is a more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Similar to somatostatin, this agent also suppresses the luteinizing hormone response to gonadotropin-releasing hormone, decreases splanchnic blood flow, and inhibits the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone.",fdaUniiCode:"RWM8CCW8GP",identifier:"C711",preferredName:a,semanticType:"Amino Acid, Peptide, or Protein",subclassOf:["C62799"],synonyms:["D-Phenylalanyl-L-cysteinyl-L-phenyl-alanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide Cyclic (2-\u003E7)-Disulfide","D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol Cyclic (2-\u003E7)-Disulfide","D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hyroxymethyl)propyl]-L-cysteinamide, Cyclic (2-\u003E7)-disulfide","OCTREOTIDE",a,"SMS-201-995","octreotide"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FOctreotide",extension:".json",createdAt:b,updatedAt:b}}],fetch:{},mutations:void 0}}("Octreotide","2021-10-30T13:43:35.183Z")));